In NB, RA treatment may benefit most from combination with a BCL-2-/BCL-XL-inhibitor such as navitoclax or APG-1252, as both proteins seem to be involved in the RA response and provide relevant targets. This evidence concerns the gene BCL2L1 and neuroblastoma.